NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals declared that its board has initiated a share buyback plan on Thursday, August 10th 2017, which permits the company to repurchase $20,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) issued its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.13. The business had revenue of $58.40 million for the quarter, compared to the consensus estimate of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.39%. The company's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.09 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

6 Wall Street analysts have issued 1 year target prices for Amphastar Pharmaceuticals' stock. Their predictions range from $18.00 to $26.00. On average, they anticipate Amphastar Pharmaceuticals' share price to reach $21.20 in the next twelve months. This suggests a possible upside of 25.9% from the stock's current price. View Analyst Ratings for Amphastar Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Amphastar Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Amicus Therapeutics (FOLD), The Medicines (MDCO), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Intercept Pharmaceuticals (ICPT), Blueprint Medicines (BPMC), Evotec (EVTCY), Emergent Biosolutions (EBS), Heron Therapeutics (HRTX), Portola Pharmaceuticals (PTLA), Endo International (ENDP), Spectrum Pharmaceuticals (SPPI) and Akcea Therapeutics (AKCA).

News stories about AMPH stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also gave headlines about the company an impact score of 45.39 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Amphastar Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.28%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $16.84.

Amphastar Pharmaceuticals has a market capitalization of $763.07 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]